Sharon Osbourne and Ozempic: separating the science from celebrity weight loss buzz

What did @thoughtswgracie2.0 actually say?

The creator made several claims about Sharon Osbourne's reported weight loss experience with semaglutide, and about the drug's safety profile more broadly. The core argument: Ozempic causes gastroparesis, thyroid tumors, and unknown long-term harm, and people are misusing it by taking Ozempic to get the weight-loss benefits of Wegovy.

Specific claims included that Osbourne is "under 100 pounds" and "can't keep weight on," that semaglutide "caused thyroid tumors in animals," that Osbourne's "stomach's probably paralyzed," and that the drug is essentially untested for long-term weight management use. The creator also suggested people are gaming the system by using Ozempic to avoid the BMI threshold required for Wegovy prescriptions.

The video has 3.4 million views. That reach matters when the claims are a mixed bag of real science, misrepresentation, and speculation presented as fact.

Does the science back this up?

Partially. The thyroid tumor concern is real but significantly overstated for human risk. The gastroparesis concern is legitimate. The framing of Ozempic as essentially untested is flat wrong.

On thyroid tumors: semaglutide carries an FDA black box warning for a risk of thyroid C-cell tumors, based on rodent studies. But rodent C-cell responses to GLP-1 receptor agonists appear to involve a mechanism that may not translate to humans, because human thyroid C-cells express GLP-1 receptors at far lower density than rodent C-cells. A 2023 analysis published in Diabetes Care (Bezin et al.) found no statistically significant increase in medullary thyroid carcinoma risk in a large French cohort of GLP-1 RA users. The warning exists because we cannot fully rule it out, not because evidence confirms it happens in humans.

On gastroparesis: a 2023 JAMA study (Sodhi et al.) found GLP-1 receptor agonist users had a meaningfully higher risk of gastroparesis compared to those using bupropion-naltrexone for weight loss. This is a real, documented adverse effect, not speculation. The creator's framing is loose, but the underlying concern has evidence behind it.

On long-term data: the SUSTAIN and STEP trial programs span multiple years and include cardiovascular outcome data. Calling semaglutide essentially untested is not accurate.

What did they get wrong (or right)?

Wrong on mechanism and magnitude. The creator says "it caused thyroid tumors in animals, like what do you think it's going to do to us?" That logical leap is not supported by current human evidence. Animal-to-human extrapolation for this specific risk has been studied and, so far, not confirmed in humans. Presenting rodent data as a direct human warning without that context is misleading.

Also wrong on the Ozempic-versus-Wegovy framing. Ozempic and Wegovy contain the same molecule, semaglutide, but at different approved doses and with different FDA indications. Someone using Ozempic off-label for weight loss is not doing something chemically exotic, though it raises real questions about dosing and insurance coverage. Compounded versions of semaglutide are a separate issue entirely, and the creator does not distinguish between these scenarios.

Right on gastroparesis risk being real. Right that long-term data in non-diabetic populations is still accumulating. Right that significant, unintended weight loss that continues past a healthy threshold is a serious clinical problem, whatever the cause. Those points deserved more precision, but the instinct was not wrong.

What should you actually know?

If you or someone you know is experiencing unintended continued weight loss or inability to eat while on a GLP-1 receptor agonist, that is a reason to contact a prescribing clinician immediately, not a reason to make a TikTok. Gastroparesis and severe nausea leading to malnutrition are documented adverse effects that require medical management.

The thyroid tumor warning on the Ozempic and Wegovy label is real and worth knowing about. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated from using these drugs. That is not a fringe concern, it is in the prescribing information. But the creator's framing, that animal tumors tell us directly what happens to humans, skips over the mechanistic and epidemiological evidence that complicates that picture.

Long-term safety data is still being collected for obesity indications specifically. That is a fair point. The SELECT trial (Lincoff et al., 2023, NEJM) showed cardiovascular benefit in non-diabetic adults with obesity, which is meaningful long-term outcome data. More will follow. "We don't know long-term effects" is partially true and partially outdated.

The bottom line on this video

This video has a kernel of legitimate concern wrapped in imprecise science and emotional framing. The gastroparesis risk is real. Long-term data gaps exist. Unintended extreme weight loss is a medical problem. But the thyroid tumor claim as presented is misleading, the "untested" framing is inaccurate, and 3.4 million people saw a version of semaglutide's risk profile that was more alarming than the evidence supports. That is not responsible health communication, even when the underlying worry has some basis.